The role of pharmacogenetic testing in predicting antipsychotic-induced adverse reactions
I.P. Pavlov Russian Medical Biological Herald · 30.06.2026 · 34 (2) · 289-298
DOI: 10.17816/pavlovj627554 ↗Kurz gefasst
Fachartikel in der Zeitschrift I.P. Pavlov Russian Medical Biological Herald, online erschienen am 30.06.2026. Verfasst von Regina F. Nasyrova und 5 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: A schizoaffective disorder is a chronic, endogenous mental disorder requiring a long-term therapy, primarily with antipsychotic drugs. This group of medications is characterized by a high risk of adverse reactions (ARs), including serious ones. Potentially fatal ARs include prolongation of QT interval with associated risk of life-threatening ventricular arrhythmias, as well as granulocytopenia. A personalized approach to selecting antipsychotic therapy, among other things, through the use of pharmacogenotyping, can help avoid antipsychotic-induced ARs. AIM: To demonstrate a method for predicting ARs during antipsychotic therapy. The paper presents a clinical case of a patient with a schizoaffective disorder and history of a prolonged intake of antipsychotics and ARs associated with them (prolongation of QT, granulocytopenia). Pharmacogenetic testing determined a pharmacological profile of the patient (poor metabolizer) and identified genetic markers associated with decreased functional activity of liver cytochrome P450 isoenzymes 2С19, 2D6 and 1А2, which play a key role in antipsychotic drug metabolism. No genetic predisposition to 3А4 isoenzyme dysfunction was detected. As a result, the mechanism of slow utilization of this group of drugs was verified, and the most optimal antipsychotic — one metabolized by 3A4 isoenzyme, was selected. Predictive pharmacogenetic testing (before prescribing an antipsychotic) could have prevented the development of adverse reactions in the patient and reduced the length of inpatient treatment. CONCLUSION: The described clinical case demonstrates that the widespread implementation of a personalized approach to selection of psychopharmacotherapy using pro-reactive rather than reactive, pharmacogenetic testing can increase safety of antipsychotic therapy in clinical practice.
Zitieren
APA
Nasyrova, R. F., Kidyaeva, A. V., Boyko, I. R., Bader, V. V., Petrova, M. M., & Shnayder, N. A. (2026). The role of pharmacogenetic testing in predicting antipsychotic-induced adverse reactions. I.P. Pavlov Russian Medical Biological Herald, 34(2), 289-298. https://doi.org/10.17816/pavlovj627554
Vancouver
Nasyrova RF, Kidyaeva AV, Boyko IR, Bader VV, Petrova MM, Shnayder NA. The role of pharmacogenetic testing in predicting antipsychotic-induced adverse reactions. I.P. Pavlov Russian Medical Biological Herald. 2026;34(2):289-298. doi:10.17816/pavlovj627554
BibTeX
@article{Nasyrova2026,
author = {Nasyrova, Regina F. and Kidyaeva, Alla V and Boyko, Irina R. and Bader, Violetta V. and Petrova, Marina M. and Shnayder, Natalia A.},
title = {The role of pharmacogenetic testing in predicting antipsychotic-induced adverse reactions},
journal = {I.P. Pavlov Russian Medical Biological Herald},
year = {2026},
volume = {34},
number = {2},
pages = {289--298},
doi = {10.17816/pavlovj627554}
}
EUVIMED